Arvinas (NASDAQ:ARVN) PT Lowered to $90.00 at Cantor Fitzgerald

Arvinas (NASDAQ:ARVNGet Rating) had its price objective cut by analysts at Cantor Fitzgerald from $106.00 to $90.00 in a report issued on Wednesday, The Fly reports. Cantor Fitzgerald’s price objective would indicate a potential upside of 127.50% from the stock’s current price.

Several other analysts have also issued reports on the stock. Capital One Financial began coverage on shares of Arvinas in a research report on Tuesday, October 25th. They set an “overweight” rating for the company. HC Wainwright reduced their price target on shares of Arvinas from $135.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, August 5th. Citigroup cut their price objective on shares of Arvinas from $103.00 to $88.00 in a research report on Thursday, August 18th. Credit Suisse Group upped their price target on shares of Arvinas to $81.00 in a report on Tuesday, November 15th. Finally, Morgan Stanley lowered their price objective on shares of Arvinas from $63.00 to $57.00 and set an “equal weight” rating for the company in a research note on Friday, November 11th. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $79.19.

Arvinas Stock Down 2.8 %

Shares of ARVN opened at $39.56 on Wednesday. The firm has a fifty day simple moving average of $45.35 and a two-hundred day simple moving average of $45.79. Arvinas has a twelve month low of $34.90 and a twelve month high of $83.40. The stock has a market capitalization of $2.11 billion, a P/E ratio of -8.31 and a beta of 1.89.

Arvinas (NASDAQ:ARVNGet Rating) last issued its quarterly earnings results on Tuesday, November 8th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.26). The business had revenue of $30.30 million for the quarter, compared to analysts’ expectations of $44.20 million. Arvinas had a negative net margin of 225.34% and a negative return on equity of 36.12%. Sell-side analysts expect that Arvinas will post -4.67 EPS for the current fiscal year.

Institutional Trading of Arvinas

Large investors have recently bought and sold shares of the company. Capital Impact Advisors LLC lifted its position in shares of Arvinas by 9.6% in the third quarter. Capital Impact Advisors LLC now owns 8,039 shares of the company’s stock valued at $426,000 after acquiring an additional 705 shares in the last quarter. BNP Paribas Arbitrage SNC grew its stake in shares of Arvinas by 50.0% in the third quarter. BNP Paribas Arbitrage SNC now owns 26,577 shares of the company’s stock valued at $1,182,000 after buying an additional 8,856 shares in the last quarter. State Street Corp grew its stake in Arvinas by 0.5% during the 3rd quarter. State Street Corp now owns 1,086,278 shares of the company’s stock valued at $48,329,000 after purchasing an additional 5,512 shares in the last quarter. Castleark Management LLC bought a new position in Arvinas during the 3rd quarter worth approximately $1,908,000. Finally, Tang Capital Management LLC bought a new position in Arvinas during the 3rd quarter worth approximately $890,000. Institutional investors and hedge funds own 91.20% of the company’s stock.

About Arvinas

(Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Further Reading

The Fly logo

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.